Program
ganaplacide
Also written as “KAF156” and “Ganaplacide”.
In Novartis's pipeline, Non-artemisinin plasmodium falciparum inhibitor
. Its studies are mostly in Malaria · Malaria, Falciparum, led by Novartis.
Furthest: phase 2, since Dec 17, 20127 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 70 open or running | phase 2since Dec 17, 2012 | Dec 17, 2012 | none ahead |
- Named in Novartis’s own pipeline as
KLU156 (Ganaplacide + lumefantrine)
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2012First study: phase 2 study in MalariaFirst studyNCT01753323 · 43 enrolled · Thailand, Vietnam
- May 19, 2017Phase 2 study in Acute Uncomplicated Plasmodium Falciparum MalariaNCT03167242 · 524 enrolled · Burkina Faso, Gabon, India and more
- Aug 20, 2019Phase 1 study in MalariaNCT04072302 · 86 enrolled · United States
- Sep 5, 2020Phase 2 study in Malaria, FalciparumNCT04546633 · 295 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more
- Oct 6, 2021Phase 1 study in MalariaNCT05084651 · 19 enrolled · United Kingdom
- Feb 4, 2022Phase 1 study in MalariaNCT05236530 · 48 enrolled · United Kingdom
- Apr 8, 2022Phase 1 study in MalariaNCT05330273 · 14 enrolled · United Kingdom
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Non-artemisinin plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05330273Malaria · United Kingdom | 1 | Completed | Nov 22, 2022 | 14 |
| NCT05236530Malaria · United Kingdom | 1 | Completed | Oct 17, 2022 | 48 |
| NCT05084651Malaria · United Kingdom | 1 | Completed | May 13, 2022 | 19 |
| NCT04546633Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Completed | Aug 13, 2024 | 295 |
| NCT04072302Malaria · United States | 1 | Completed | Nov 29, 2017 | 86 |
| NCT03167242Acute Uncomplicated Plasmodium Falciparum Malaria · Burkina Faso, Gabon, India and more | 2 | Completed | Jun 14, 2021 | 524 |
| NCT01753323Malaria · Thailand, Vietnam | 2 | Completed | Aug 2014 | 43 |
How it is read
Names in the registry
- “KAF156”, 4 entries
- “Ganaplacide”, 4 entries
Conditions, from the studies’ own filings
- Malaria, 5 studies
- Malaria, Falciparum, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.